Pharmacyclic’s Co-Development Pact With Janssen Carries Largest Single-Asset Upfront Payment Of 2011
The two companies will co-develop and co-commercialize PCI-32765, which is being investigated in multiple types of hematological cancer.
The two companies will co-develop and co-commercialize PCI-32765, which is being investigated in multiple types of hematological cancer.